. Author manuscript; available in PMC: 2023 Mar 2.

Published in final edited form as: J Clin Oncol. 2022 Feb 10;40(14):1542–1551. doi: 10.1200/JCO.21.01647

Table 3. Evaluation of clinical criteria with grade.

Criteria	BC + Grade^*	TNBC^*	Bilateral^*	FHBC^*	FHOC^*	Eligible patients (%)^**	BRCA PVs carriers (%)^**	Detection ratio
MCC 29	≤40	≤45	≤60			30.0	63.0	12 : 1
MCC 17	≤40	≤60	≤60	≤60	≤60	31.0	64.0	13 : 1
MCC 33	≤40	≤50	≤60	≤60		32.0	66.0	12 : 1
NCCN with grade	≤45	≤60	46-50	46-50		33.0	69.0	12 : 1
MCC 45	≤40	≤60	≤60	46-50		38.0	71.0	14 : 1
MCC 10	≤45	≤50	≤60	≤60	≤60	36.0	71.0	13 : 1

Sample: 2448 MyBrCa and SGBCC breast cancer patients in single imputed validation set.

Abbreviations: MCC, Modified Clinical Criteria; BC, Breast Cancer of proband; TNBC, Triple Negative Breast Cancer; Bilateral, Bilateral Breast Cancer; OC, Ovarian Cancer; FHBC, one or more first degree relatives with Breast Cancer; FHOC, one or more first degree relatives with Ovarian Cancer.

Age of diagnosis for breast cancer of proband.

^**

Fulfilled at least one criterion.